Stabilizers of the Max Homodimer Identified in Virtual Ligand Screening Inhibit Myc Function

Many human cancers show constitutive or amplified expression of the transcriptional regulator and oncoprotein Myc, making Myc a potential target for therapeutic intervention. Here we report the down-regulation of Myc activity by reducing the availability of Max, the essential dimerization partner of Myc. Max is expressed constitutively and can form unstable homodimers. We have isolated stabilizers of the Max homodimer by applying virtual ligand screening (VLS) to identify specific binding pockets for small molecule interactors. Candidate compounds found by VLS were screened by fluorescence resonance energy transfer, and from these screens emerged a potent, specific stabilizer of the Max homodimer. In vitro binding assays demonstrated that the stabilizer enhances the formation of the Max-Max homodimer and interferes with the heterodimerization of Myc and Max in a dose-dependent manner. Furthermore, this compound interferes with Myc-induced oncogenic transformation, Myc-dependent cell growth, and Myc-mediated transcriptional activation. The Max-Max stabilizer can be considered a lead compound for the development of inhibitors of the Myc network.

[1]  M. Eilers,et al.  Control of cell proliferation by Myc family genes. , 1999, Molecules and cells.

[2]  P. Vogt,et al.  The Catalytic Subunit of Phosphoinositide 3-Kinase: Requirements for Oncogenicity* , 2000, The Journal of Biological Chemistry.

[3]  F. Orr,et al.  C‐myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells , 2002, International journal of cancer.

[4]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[5]  E. Prochownik,et al.  MYC oncogenes and human neoplastic disease , 1999, Oncogene.

[6]  D. Goodsell,et al.  Identifying Protein Binding Sites and Optimal Ligands , 2005 .

[7]  M. Urashima,et al.  Max protein expression is associated with survival of children with lymphoblastic lymphoma , 1999, Pediatrics international : official journal of the Japan Pediatric Society.

[8]  T. Berg.  Modulation of protein-protein interactions with small organic molecules. , 2003, Angewandte Chemie.

[9]  Luhua Lai,et al.  A New Atom-Additive Method for Calculating Partition Coefficients , 1997, J. Chem. Inf. Comput. Sci..

[10]  Howard Y. Chang,et al.  Genetic regulators of large-scale transcriptional signatures in cancer , 2006, Nature Genetics.

[11]  B. Kräutler,et al.  Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc. , 2001, Journal of molecular biology.

[12]  P. Vogt,et al.  Defectiveness of avian myelocytomatosis virus MC29: isolation of long-term nonproducer cultures and analysis of virus-specific polypeptide synthesis. , 1977, Virology.

[13]  C. Cultraro,et al.  Transfected wild-type and mutant max regulate cell growth and differentiation of murine erythroleukemia cells. , 1993, Oncogene.

[14]  A. Olson,et al.  Discovery of acetylcholinesterase peripheral anionic site ligands through computational refinement of a directed library. , 2005, Biochemistry.

[15]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[16]  K. Alitalo,et al.  Repression of cyclin D1: a novel function of MYC. , 1994, Molecular and cellular biology.

[17]  Sarah B. Tegen,et al.  Activated Src abrogates the Myc requirement for the G0/G1 transition but not for the G1/S transition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Dang,et al.  Myc target transcriptomes. , 2006, Current topics in microbiology and immunology.

[19]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[20]  P. Vogt.  Spontaneous segregation of nontransforming viruses from cloned sarcoma viruses. , 1971, Virology.

[21]  S. Hughes,et al.  Comparative analysis of the structure and function of the chicken c-myc and v-myc genes: v-myc is a more potent inducer of cell proliferation and apoptosis than c-myc. , 1996, Oncogene.

[22]  D. Boger,et al.  Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. van der Spoel,et al.  Efficient docking of peptides to proteins without prior knowledge of the binding site , 2002, Protein science : a publication of the Protein Society.

[24]  A. Sewing,et al.  Cyclins D1 and D2 mediate Myc‐induced proliferation via sequestration of p27Kip1 and p21Cip1 , 1999, The EMBO journal.

[25]  M. Eilers,et al.  Contributions of Myc to tumorigenesis. , 2002, Biochimica et biophysica acta.

[26]  I. Wilson,et al.  Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identify novel nonfolate inhibitors. , 2004, Journal of medicinal chemistry.

[27]  R. Eisenman,et al.  Myc and Max associate in vivo. , 1992, Genes & development.

[28]  Natasja Brooijmans,et al.  Molecular recognition and docking algorithms. , 2003, Annual review of biophysics and biomolecular structure.

[29]  Ariele Viacava Follis,et al.  Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. , 2008, Chemistry & biology.

[30]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[31]  R. Eisenman,et al.  Overexpressed max is not oncogenic and attenuates myc-induced lymphoproliferation and lymphomagenesis in transgenic mice. , 1995, Oncogene.

[32]  M. Cole,et al.  The Novel ATM-Related Protein TRRAP Is an Essential Cofactor for the c-Myc and E2F Oncoproteins , 1998, Cell.

[33]  Marc Flajolet,et al.  Discovery of protein phosphatase 2C inhibitors by virtual screening. , 2006, Journal of medicinal chemistry.

[34]  P. Vogt,et al.  A credit-card library approach for disrupting protein-protein interactions. , 2006, Bioorganic & medicinal chemistry.

[35]  Stephen K. Burley,et al.  X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.

[36]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[37]  B. Lüscher,et al.  Function and regulation of the transcription factors of the Myc/Max/Mad network. , 2001, Gene.

[38]  R. Eisenman,et al.  Myc and Max proteins possess distinct transcriptional activities , 1992, Nature.

[39]  P. Vogt,et al.  Avian sarcoma virus 17 carries the jun oncogene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Eisenman,et al.  Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. , 1991, Science.

[41]  E. Prochownik,et al.  Lack of transcriptional repression by max homodimers , 1998, Oncogene.